奈西立肽在急性心肌梗死中的应用  

Application of nesiritide in acute myocardial infarction

作　　者：孙佳莹 马淑梅[1] SUN Jia-ying MA Shu-mei(Shengjing Hospital of China Medical University, Shenyang 110004 ,China)

机构地区：[1]中国医科大学附属盛京医院,沈阳110004

出　　处：《实用药物与临床》2017年第10期1216-1219,共4页Practical Pharmacy and Clinical Remedies

摘　　要：奈西立肽是采用基因重组技术制成的rh BNP,临床上主要用于心力衰竭的治疗。其通过抑制多种细胞因子和神经内分泌因子的激活,改善并逆转左室重构。奈西立肽可补充急性心肌梗死时内源性BNP代偿不足,使局部BNP的合成、分泌增加,促进心脏内环境恢复稳定,有效遏制急性心脏毒性和慢性心脏重塑。本文就奈西立肽在急性心肌梗死治疗中的机制、现状与进展进行综述。As one of rhBNP,nesiritide is produced by gene recombinant technology. It is mainly used in the clinical treatment for heart failure. Nesiritide inhibits the activation of endogenous neuroendocrine and cytokines, improving or reversing the left ventricular remodeling. It can supplement the compensatory insufficiency of endogenous BNP in acute myocardial infarction, increase the synthesis and secretion of local BNP, and promote heart internal environment to restore stability, thus effectively curbing the acute cardiotoxicity and chronic cardiac remodeling. This paper reviews the mechanism, current status and progress of the effect of nesiritide on acute myocardial infarction.

关 键 词：奈西立肽 急性心肌梗死 心功能 

分 类 号：R542.22[医药卫生—心血管疾病]